A Study Investigating the Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany for Participants With Relapsing-remitting Multiple Sclerosis Treated With Ozanimod (Zeposia®)
CompletedOBSERVATIONAL
Enrollment
450
Participants
Timeline
Start Date
March 3, 2021
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2025
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG
Ozanimod
As per product label
Trial Locations (1)
01307
Universitätsklinikum Dresden, MS Ambulanz, Dresden